Skip to main content

Table 1

From: Reduction in oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma receiving omalizumab in a real-world setting

 

Baseline N=916

12 months N=734

24 months N=643

Patients on OCS maintenance monotherapy, n (%)

262 (28.6)

118 (16.1)

91 (14.2)

Mean (SD) total daily OCS dose*, mg

15.49 (14.01)a

7.68 (10.94)b

5.77 (8.89)c

Mean (SD) reduction from baseline in total daily dose, mg

-

7.89 (13.77)b

9.95 (15.58)c

Patients with alteration in total OCS dose, n (%)

   

• discontinuation

-

77 (40.7)b

82 (48.8)c

• reduction

-

31 (16.4)b

34 (20.2)c

• no change

-

76 (40.2)b

48 (28.6)c

• increased

-

5 (2.6)b

4 (2.4)c

Mean (SD) time to either reduction or discontinuation of OCS, days

-

198.5 (114.29)d

291.2 (210.86)e

  1. * OCS dose was reported in prednisolone equivalent dose as mg per day. OCS – oral corticosteroid; SD – standard deviation; n – number of patients who received OCS at baseline and who provided OCS information at 12 months and 24 months (an=246; bn=189; cn=168; dn=108; en=116).